James Wright
Psychiatry · Houston, TXNPI 1730256363
Payments from drug & device makers
Across 214 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$791
- Otsuka America Pharmaceutical, Inc.$722
- Lundbeck LLC$484
- Almatica Pharma LLC$376
- Corium, LLC$213
- Bausch Health US, LLC$177
- plus $856 from 13 others
What the payments were for
- Food & beverage$3,57299%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $791 |
| Otsuka America Pharmaceutical, Inc. | 38 | $722 |
| Lundbeck LLC | 28 | $484 |
| Almatica Pharma LLC | 19 | $376 |
| Corium, LLC | 17 | $213 |
| Bausch Health US, LLC | 10 | $177 |
| Neurocrine Biosciences, Inc. | 8 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $155 |
| Johnson & Johnson | 6 | $111 |
| Validus Pharmaceuticals LLC | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Neuronetics, Inc. | 3 | $36 |
| Alkermes, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $18 |
| Eisai Inc. | 1 | $12 |
How this compares
$3,618 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 38 | $63,519 |
| TrintellixVortioxetine Hydrobromide | 34 | $26,996 |
| Aripiprazole | 47 | $18,436 |
| Lisdexamfetamine Dimesylate | 45 | $10,414 |
| Lurasidone Hcl | 62 | $10,187 |
| Seroquel XrQuetiapine Fumarate | 12 | $9,137 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $8,892 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 170 | $7,721 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 85 | $4,555 |
| Methylphenidate ErMethylphenidate Hcl | 23 | $4,437 |
| Bupropion XlBupropion Hcl | 108 | $3,733 |
| Memantine Hcl | 27 | $3,399 |
| Vilazodone Hcl | 27 | $3,153 |
| Alprazolam | 304 | $2,582 |
| Lorazepam | 149 | $2,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $722 | $63,51938 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $155 | $35,88850 claims |
| Almatica Pharma LLCSertraline Hcl | $376 | $48222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.